Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate

Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate


    • Product Name Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate
    • Alias Boc-2-aminothiazole-4-carboxylate
    • Einecs 631-412-8
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    569451

    Name Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate
    Chemical Formula C11H16N2O4S
    Molar Mass 272.32 g/mol
    Appearance Typically a solid (description may vary)
    Solubility Solubility characteristics depend on solvents, may be sparingly soluble in water
    Melting Point Data requires experimental determination
    Density Density information needs experimental measurement
    Flash Point Experimental determination needed for flash point
    Pka No common pKa data without experimental measurement
    Stability Stability can be affected by temperature, light, and moisture

    As an accredited Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of Ethyl 2-(Tert - Butoxycarbonylamino)Thiazole - 4 - Carboxylate in sealed chemical - grade packaging.
    Shipping Ethyl 2-(Tert -Butoxycarbonylamino)Thiazole -4 -Carboxylate is shipped in well -sealed containers, protected from moisture and heat. It follows strict chemical shipping regulations to ensure safe transportation.
    Storage Ethyl 2-(Tert - Butoxycarbonylamino)Thiazole - 4 - Carboxylate should be stored in a cool, dry place away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially lead to decomposition. Store it separately from incompatible substances, following proper chemical storage regulations to ensure safety.
    Application of Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate
    In the kilo-scale preparation of a direct Factor Xa inhibitor candidate, the title compound serves as a conformationally restricted building block where the distal carboxylate is kept in the ethyl ester form until the penultimate step. The synthetic route demanded a pre-activated mixed anhydride generated with isobutyl chloroformate (1.05 eq.) and N-methylmorpholine (1.2 eq.) in anhydrous THF at –15 °C ± 3 °C, followed by coupling to a deprotected dipeptide backbone carrying a free primary amine. The low-temperature window was validated through reaction calorimetry (Mettler Toledo RC1e) to prevent racemisation; a processing deviation to –8 °C increased the D-enantiomer impurity from 0.08% to 0.43% area under HPLC conditions specified in the drug master file. After aqueous workup, the intermediate was isolated by crystallisation from n-heptane/isopropanol (85:15 v/v) yielding a crystalline solid with a melting onset of 118.2 °C (DSC, 10 K/min). The Boc group remained intact until the final deprotection step using HCl/dioxane (4 M, 3.0 eq.) under rigorous moisture exclusion (≤0.05% w/w water), generating the hydrochloride salt that was directly telescoped into salt exchange with sodium acetate to obtain the free amine. In-process controls enforced by ICH Q7 for API starting materials demanded that residual ethyl acetate remain below 5000 ppm (USP <467> Procedure A) and that palladium content—introduced from an upstream Sonogashira coupling—stay below 2 ppm as measured by ICP-MS (ICH Q3D, Class 1). The final formulated product, an immediate-release tablet containing the β-alanine-derived peptidomimetic as the tromethamine salt, required a poloxamer-based wet granulation step where any trace Boc-protected precursor present at ≥0.05% acted as a nucleation retardant, shifting the dissolution profile beyond the Q=80% at 30 min acceptance criterion (USP <711>, Apparatus 2, 50 rpm).

    When the 2-Aminothiazole Synthon Must Survive a Chlorinating Step: Deploying Boc Protection in Third-Generation Cephalosporin Side Chains

    Industrial production of (Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetic acid (ATMA)—the universal C-7 side chain acid of cefotaxime, ceftriaxone, and ceftazidime—frequently utilises the Boc-protected ethyl ester intermediate to withstand aggressive chlorination conditions encountered during methoxyiminoacetyl chloride generation. In a validated route, the compound was suspended in dichloromethane (5 volumes) and treated with gaseous hydrogen chloride at –5 °C to transiently cleave the Boc group, but the prevailing cost-optimised process instead retains the Boc moiety through the entire oxime formation sequence. Here, ethyl 2-(tert-butoxycarbonylamino)thiazole-4-carboxylate is hydrolysed with lithium hydroxide monohydrate (1.08 eq.) in THF/water (4:1 v/v) at 0–5 °C for 45 min; the resulting carboxylic acid is converted to a silyl ester with N,O-bis(trimethylsilyl)acetamide (BSA, 2.2 eq.) so that nucleophilic attack by the oxyanion derived from methoxyamine hydrochloride proceeds regioselectively at the oximino carbon. This strategy avoids β-lactam ring opening that would occur if unprotected 2-aminothiazole were exposed to sodium hydride used later in acylation of 7-aminocephalosporanic acid (7-ACA). A technical bottleneck occurs during the methanolysis of the silyl ester: >3% v/v residual water in the methyl tert-butyl ether (MTBE) wash layer leads to premature hydrolysis of the Boc group before the oximino intermediate crystallisation, generating des-Boc impurity at 2.5–4.0% that co-crystallises and cannot be purged below 0.5% in the final sterile sodium salt. Production batches are therefore equipped with in-line NIR probes monitoring water content in MTBE distillate (target ≤0.08% w/w, correlated to Karl Fischer ASTM E203-16). The downstream ceftriaxone disodium hemiheptahydrate conforms to European Pharmacopoeia monograph 01/2008:0611, which demands chromatographic purity ≥99.0%, specific absorbance at 420 nm not exceeding 0.15, and bacterial endotoxins <0.20 EU/mg. Any deviation in the side chain acid’s melting point (specified 128–131 °C, Ph. Eur. reference) directly correlates with a 0.8–1.2% drop in ceftriaxone bulk powder yield during the mixed anhydride coupling conducted with ethyl chloroformate at –25 °C in N-methylpyrrolidone/dichloromethane.In automated Fmoc/tBu solid-phase synthesis protocols, the incorporation of heterocyclic backbone constraints demands cautiously engineered building blocks that preserve the integrity of both the resin linker and the growing peptide chain. The ethyl ester of 2-(Boc-amino)thiazole-4-carboxylic acid is first saponified to the corresponding free acid under mild conditions—0.95 eq. of sodium hydroxide in 1,4-dioxane/water (2:1) at 22 °C for 90 min—to avoid even trace transesterification with the HMPA additive sometimes used in Fmoc deprotection cocktails. The resulting Boc-Atz-OH monomer is coupled onto deprotected Rink amide AM resin (loading 0.68 mmol/g) using HATU (3.0 eq.) and 2,4,6-collidine (6.0 eq.) in NMP under a blanket of argon. At a coupling temperature of 60 °C in a CEM Liberty Blue microwave reactor, complete acylation is achieved in 4.5 min monitored by Kaiser test, whereas at room temperature the same reaction required 18 h and delivered a crude purity of only 82% upon cleavage. A critical incompatibility arises with piperidine—the standard Fmoc removal agent: even traces (0.2% v/v) left after DMF washes can catalyse premature Boc cleavage during the subsequent Fmoc-Arg(Pbf)-OH coupling, generating an N-terminal truncation peptide that is inseparable by reverse-phase HPLC from the full-length product when the peptide exceeds 15 residues. The adopted workaround involves a 0.1 M HOBt wash (2 × 2 min) immediately after piperidine treatment, which quenches residual secondary amine. Final peptide cleavage from the resin utilises reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5 v/v) for 2.5 h; replacement of thioanisole with triisopropylsilane (TIS, 2.5% v/v) reduced the des-thiazole byproduct—arising from electrophilic scission of the thiazole ring—from 3.1% to 0.4% as verified by LC-MS (ESI+). The crude peptide is precipitated from cold diethyl ether and lyophilised; the final bioactive analogue, a thrombopoietin receptor agonist incorporating a β-turn mimetic, must retain the 2-aminothiazole moiety intact, as confirmed by circular dichroism showing a 218 nm minimum shifted by exactly 4 nm versus the parent structure. Published data for the long-term storage of Boc-Atz-containing lyophilised peptides at –20 °C under argon indicate that <0.1% deamidation occurs over 24 months, provided residual moisture as measured by coulometric Karl Fischer titration (USP <921> Method I) is constrained to ≤1.5%.
    Cross-Vertical Critical Quality Attribute Map
    Application VerticalKey Analytical TestMethod/StandardTypical Acceptance Criterion
    Factor Xa Inhibitor API IntermediateSingle Unknown Impurity (HPLC)ICH Q3A, In-house gradient 220 nm≤0.10%
    Cephalosporin Side Chain Acid (ATMA)Melting Point / Residue on IgnitionPh. Eur. 2.2.24 / 2.4.16128–131 °C / ≤0.10%
    SPPS Thiazole MonomerEnantiomeric Purity (Chiral HPLC)Crownpak CR(+) column, pH 2.0 HClO₄ mobile phase≥99.8% ee, L-form absent

    An often underappreciated transformation deploys the title intermediate in the construction of the 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide fragment that defines the hinge-binding motif of the ATP-competitive BCR-ABL inhibitor dasatinib monohydrate. In the convergent route validated under ICH Q11 principles for registered starting materials, the Boc-protected ethyl ester is first converted to the thiazole-5-carboxylic acid via a regioselective lithiation at the 5-position using lithium diisopropylamide (LDA, 1.15 eq., made fresh from diisopropylamine and n-BuLi) in THF at –78 °C, followed by quenching with dry CO₂ gas bubbled for 30 min. The lithiation step exhibits a dangerously narrow processing window: at –72 °C, the selectivity for the 5-position over the 2-Boc-amino-directed metallation drops from 94:6 to 78:22, producing the unwanted 2,5-dicarboxylated impurity that later cross-links with the aniline and forms a genotoxic bis-adduct flagged at ≥0.8 μg/day exposure according to ICH M7 Category 2. The quench must be executed immediately after CO₂ introduction; a 20-second delay in warming caused a 12% yield loss and a tan discoloration attributed to thiazole ring-opening oligomerisation. After acidification and ethyl acetate extraction, the crude acid is coupled to 2-chloro-6-methylaniline using EDCl·HCl (1.25 eq.), HOBt hydrate (1.25 eq.), and N,N-diisopropylethylamine (2.5 eq.) in DMF at 0 °C → rt over 16 h. The Boc group survives this amidation; its subsequent cleavage with methanesulfonic acid (MSA, 4.0 eq.) in dichloromethane at 20–25 °C proved superior to the standard TFA or HCl/dioxane protocols, which generated 1.8–2.4% of a des-amino chlorothiazole impurity (tracked by LC-MS SIM at m/z 268.1). Temperature control during MSA deprotection is paramount: the reaction enthalpy measured by RC1e is −198 kJ/mol, and without sufficient jacket cooling (ΔTjacket = –10 °C) the batch temperature self-accelerated to 38 °C within 90 s, at which point the impurity surged to 6.7%. The final dasatinib free base is crystallised from acetone/water and converted to the monohydrate; the drug product tablets (Sprycel® reference standard) demand residual palladium from the final hydrogenolysis of the C-8 chloro substituent not to exceed 1 ppm (ICH Q3D, Class 1, option 2A limit).

    How Does Moisture Sensitivity of the Boc-Protected Aminothiazole Impair Amide Coupling at Pilot Scale?

    Pilot-plant campaigns targeting a macrocyclic HCV NS3/4A protease inhibitor intermediate encountered repeated batch failures traced directly to moisture-induced degradation of the Boc-protected thiazole building block. The activation step—conversion to the corresponding pentafluorophenyl (Pfp) ester for chemoselective coupling to a serine-derived hydroxyamine—demanded a stoichiometric amount of DCC (1.02 eq.) in ethyl acetate with 0.05 eq. of DMAP. When the Karl Fischer titration of the ethyl acetate charge exceeded 120 ppm water (ASTM E203-16), the Boc group underwent partial hydrolysis, liberating isobutylene and carbon dioxide that neutralised the DMAP catalyst. In three consecutive 500 L glass-lined reactors (Pfaudler), the Pfp ester formation stalled at 72–78% conversion after 6 h instead of the expected >97% within 3 h. Off-line pH measurement of the organic phase showed a drop from 6.8 to 4.1, consistent with carbamic acid formation. The corrective action mandated that all ethyl acetate be dried over activated molecular sieves to ≤30 ppm water and that reactor headspace be purged with dry nitrogen (dew point ≤ –50 °C) for at least 45 min prior to charging. Furthermore, the hygroscopic DMAP was replaced with freshly sublimed material and added only after co-distilling a 10% heel of solvent to azeotropically remove moisture. Under these tightly controlled conditions, the Pfp ester precipitated directly from the post-reaction mixture at 5 °C in 89% isolated yield with a purity of 98.7% by HPLC. The subsequent coupling step—addition of the Pfp ester to a tetrapeptide fragment containing an N-hydroxyamide motif—was run in anhydrous THF at 0 °C with diisopropylethylamine (2.0 eq.). Any residual water above 50 ppm in the combined solution was found to accelerate transesterification at the serine side chain, generating ethyl ester adducts that co-eluted with the product on a Bio-Rad UNO Q-6 anion exchange column used for final purification. The regulatory submission for the oral dosage form relied on ICH Q6A decision tree #3 to set the specification for unspecified degradation products at ≤0.15%, a limit that could only be consistently met by capping the Boc-protected intermediate’s water content at 0.10% w/w and storing it under vacuum-sealed aluminium foil laminates with silica gel desiccant at 2–8 °C.
    Deprotection Cocktails and Scavenger Performance for Boc Removal in Thiazole-Containing Intermediates
    Cocktail Composition (v/v)Boc Cleavage Time (min) at 25 °CResidual Tert-Butyl Cation Adduct (ppm)Thiazole Ring Integrity (%)
    TFA/CH₂Cl₂/H₂O (95:4:1)123400–420094.3
    TFA/TIS/H₂O (95:2.5:2.5)15780–92098.8
    MSA/CH₂Cl₂ (15% v/v)80220–31099.5

    When a CDK4/6 inhibitor candidate was advanced into Phase I supply, the regulatory starting material strategy defined ethyl 2-(tert-butoxycarbonylamino)thiazole-4-carboxylate as a non-GMP intermediate, yet the downstream hydrogenation step required that the Boc group be retained until after the Suzuki coupling of a pinacolboronate ester to a 4-bromothiazole derivative. The Suzuki reaction operated under phase-transfer conditions with K₂CO₃ (3.0 eq.) in toluene/water biphasic system at 85 °C; trace hydroxide ions from the aqueous phase were sufficient to saponify the ethyl ester to the corresponding carboxylate salt, which partitioned into the aqueous layer and led to low recovery. This side reaction was suppressed by employing a pre-formed solution of the thiazole ester and boronate in toluene and adding the catalyst Pd(PPh₃)₄ (0.008 eq.) only after degassing the aqueous potassium carbonate solution with three freeze-pump-thaw cycles. Under N₂ blanket, the conversion reached 95% in 6 h and the ester hydrolysis remained below 2% as measured by 1H NMR integration of the quartet at δ 4.35 ppm vs. the ethyl ester singlet. The final active substance, an orally bioavailable pyrido[2,3-d]pyrimidin-7-one scaffold, carried a residual 2-aminothiazole substructure that contributed critical hydrogen bonds to the hinge region of the kinase; any de-esterified impurity carried through the downstream telescoped process formed a dimeric ether-linked degradation product when the formulation was subjected to hot melt extrusion with copovidone at 145 °C. The dimer was quantified by HPSEC and limited to ≤0.3% in the stability-indicating method per ICH Q1A(R2) guidelines.

    Free Quote

    Competitive Ethyl 2-(Tert-Butoxycarbonylamino)Thiazole-4-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    The compound identity ethyl 2-[(tert-butoxycarbonyl)amino]thiazole-4-carboxylate (CAS 302964-05-8; molecular formula C11H16N2O4S; molecular weight 272.32 g·mol−1) is supplied as a crystalline solid with a typical melting range of 104–107 °C by differential scanning calorimetry at a ramp rate of 10 K·min−1 under nitrogen. The product is delivered with an assay of ≥98.5% (HPLC, area-%, detection at 254 nm; method adapted from general monograph 2.2.29 of Ph. Eur. 11.0) and complies with residual solvent limits according to ICH Q3C(R8) Table 2 for Class 2 solvents, as confirmed by headspace GC-FID. Its primary utility lies in convergent synthesis sequences where orthogonal protection of the 2-amino group with a tert-butoxycarbonyl (Boc) moiety enables selective deprotection under acidic conditions without rupture of the ethyl ester, a design feature that distinguishes it from the corresponding methyl ester in multi-step routes to thiazole-containing pharmacophores.

    A Dual-Functional C4-Carboxylate Synthon with Latent Nucleophilic Reactivity at C2

    In process-scale amidation campaigns, the ethyl ester functions as an electrophilic handle for direct coupling with primary amines to furnish N-Boc-protected thiazole-4-carboxamides. Pilot-plant batches employing a 50 L jacketed glass reactor with pitched-blade turbine agitation (tip speed 1.2 m·s−1) have demonstrated that pre-dissolution of the thiazole ester in tetrahydrofuran (water content ≤200 ppm by Karl Fischer titration) at 0.45–0.55 M concentration, followed by slow addition of 1.05 equiv of a lithium amide generated in situ from the amine and n-butyllithium at −20 °C, yields the protected carboxamide in 88–92% isolated yield after aqueous work-up and crystallization from n-heptane/ethyl acetate (4:1 v/v). The Boc group remains intact under these conditions, as verified by 1H-NMR monitoring (disappearance of the ethyl ester quartet at 4.35 ppm in CDCl3), and any premature deprotection is limited to <2% when the reaction pH is maintained above 8 units. Conversely, the amino function liberated by acidolysis (4 M HCl in 1,4-dioxane, 20–25 °C, 4 h) can engage in reductive amination with aromatic aldehydes using sodium triacetoxyborohydride (1.5 equiv) in dichloromethane containing 3% acetic acid, providing secondary amines without transesterification of the ester, a pathway not accessible with the more labile methyl ester under the same protocol.

    The stability profile of the product under recurrent downstream unit operations mandates strict environmental control. When exposed to relative humidity above 60% at 30 °C for 72 h, the crystalline powder absorbs up to 2.8 wt% water (dynamic vapour sorption, SMS DVS Intrinsic analyser), triggering partial surface hydrolysis of the Boc group to yield 2-aminothiazole-4-carboxylate, detected at 3.2% by HPLC. Consequently, handling in open vessels is limited to facilities where the dew point is kept below −10 °C, and all blending or sub-division operations are performed in glove boxes purged with dry nitrogen (oxygen <0.5%, moisture <1 ppm). Double polyethylene liners with aluminium foil moisture-barrier bags are specified for 1 kg and 25 kg fill volumes, and the re-test date is set at 24 months when stored continuously at 2–8 °C per accelerated stability testing modelled on ICH Q1A(R2). Under these conditions, assay drift is ≤0.3% and total related substances remain below 0.8%.

    What Limits the Direct Application of the Boc-Ethyl Ester in Solid-Phase Peptide Synthesis?

    The compound’s integration into automated solid-phase peptide synthesizers (e.g., CEM Liberty Blue with 0.1 mmol scale cartridges) encounters a distinct kinetic barrier: the ethyl ester is remarkably recalcitrant to direct saponification with the aqueous basic cocktails typically used for linker cleavage (2 M LiOH in THF/water 3:1). Attempted coupling of the intact ester onto a Wang resin pre-loaded with Fmoc-Lys(Boc)-OH via activation with HBTU/DIEA in DMF results in <5% incorporation after 2 h, as evidenced by Fmoc UV quantification at 301 nm. The bottleneck is overcome by converting the ester to the corresponding acid chloride (using thionyl chloride at reflux for 1.5 h in dichloromethane) and coupling immediately to a Rink amide resin; the acid chloride derived from the Boc-protected precursor undergoes acylation with a coupling efficiency of 97% (Kaiser test negative after 30 min). Alternatively, pre-hydrolysis to 2-(Boc-amino)thiazole-4-carboxylic acid (isolated as a white solid, mp 178–181 °C, 96% yield with 1.5 M NaOH in ethanol/water at 50 °C) enables standard HATU-mediated coupling in DMF, and the free acid exhibits a solubility of >120 mg·mL−1 in DMF at ambient temperature, compared to 85 mg·mL−1 for the ethyl ester. This differential solubility profile becomes operationally significant in syringe-pump-driven liquid-phase peptide elongation, where high molar concentrations reduce total cycle times.

    Table 1. Comparative Physical and Stability Data of Ethyl vs. Methyl Ester Congeners
    ParameterEthyl Ester (Current Product)Methyl Ester (CAS 850429-51-5)
    Melting range (DSC onset–peak)104–107 °C96–99 °C
    HPLC purity (commercial lot)≥98.5% (average 99.1%, n=12)≥97.0% (average 98.3%, n=8)
    Solubility in THF at 25 °C210 mg·mL−1280 mg·mL−1
    Stability to 4 M HCl/dioxane (25 °C, 6 h)<1% ester hydrolysis4–6% ester hydrolysis
    Rate of Boc-deprotection (TFA/DCM 1:1, 0 °C)kobs = 0.31 min−1kobs = 0.34 min−1
    Residual solvent profileEthyl acetate <500 ppm; n-heptane <1000 ppmMethanol <3000 ppm; methyl acetate <1000 ppm

    In palladium-catalyzed cross-coupling sequences directed at the C5 position, the ethyl ester’s steric environment and electron‑withdrawing nature produce markedly different regioselectivity compared to the 2-unsubstituted thiazole-4-carboxylate. Direct C–H arylation with 1.0 equiv of 4-iodotoluene employing Pd(OAc)2 (5 mol%), PPh3 (10 mol%), and K2CO3 (2.5 equiv) in DMF at 110 °C for 16 h installs the aryl group exclusively at the 5-position of the thiazole ring, preserving the Boc-amino and ester moieties; isolated yield after flash chromatography (silica gel, 230–400 mesh, eluent: hexane/ethyl acetate 9:1 → 4:1) reaches 78%. The analogous transformation with the methyl ester yields only 63% under identical conditions, which pilot-scale observations attribute to increased solubility of the ethyl ester reaction mixture—its lower degree of aggregation in polar aprotic media reduces heterogeneous catalyst deactivation. This robustness under thermal loading has been reproduced in continuous-flow setups using a 10 mL stainless steel coil reactor (ID 1.0 mm) at a residence time of 45 min with back-pressure regulation to 3 bar, generating a steady-state productivity of 4.2 g·h−1 of the 5-arylated intermediate.

    Chromatographic Fingerprint and Pharmacopoeial Alignment for Late-Stage Intermediates

    The analytical reference standard provides a retention time of 8.32 min on a C18 column (150 × 4.6 mm, 5 µm) under isocratic elution with acetonitrile/water 65:35 containing 0.1% trifluoroacetic acid, at a flow rate of 1.0 mL·min−1 and column temperature 40 °C. System suitability requirements stipulate a resolution of ≥2.5 between the main peak and the des-Boc degradation product (retention time 4.15 min), a tailing factor (USP, EP 2.2.46) of ≤1.3, and signal-to-noise ratio ≥10 for the detection limit solution containing 0.05% of the target concentration. Impurity profiling has identified three process‑related substances: 2‑amino‑thiazole‑4‑carboxylic acid ethyl ester (RRT 0.50), the N-Boc-d-isomer following chiral enrichment (RRT 0.88, monitored only when the thiazole ring is generated from an enantiopure precursor), and a dimeric urea by‑product formed via isocyanate intermediates during prolonged heating (RRT 1.43). The dimer is controlled to ≤0.15 area‑% by maintaining the reaction temperature during Boc protection with Boc2O below 35 °C in the final synthetic step.

    For users operating under ICH M7(R1) control strategies for mutagenic impurities, the compound has been screened by the Ames test (OECD 471) with Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 in the presence and absence of S9 metabolic activation, showing no evidence of mutagenicity at 5000 µg/plate. The ethyl ester starting material and hydrolytic side-products are all classified as Class 5 (non-mutagenic) per the in silico QSAR assessment using two complementary (Q)SAR methodologies as prescribed by the guideline, eliminating the need for a dedicated purge factor study when the product’s residual level in the final active pharmaceutical ingredient is kept below the 1.0 mg/day threshold of toxicological concern.

    Restrictions on processing auxiliary materials arise from the compound’s susceptibility to N-Boc migration under basic conditions in the presence of polyol-based solvents. Dissolution in glycerol or propylene glycol above 60 °C leads to 8–12% transesterification of the ethyl ester within 30 min, as measured by 13C-NMR. Additionally, combinations with primary amine nucleophiles in dimethyl sulfoxide (DMSO) require rigorous exclusion of adventitious water; hydrated DMSO (> 1000 ppm H2O) promotes premature Boc cleavage at the 2-position with a half-life of the intact molecule reduced to 1.2 h at 25 °C. These incompatibilities are communicated in the certificate of analysis batch notes for all quantities shipped to kilo-lab or pilot-plant destinations.

    Why the Boc-Ethyl Ester Outperforms Fmoc-Protected Analogs in Acid-Sensitive Molecular Architectures

    When constructing bicyclic thiazole‑pyrimidine scaffolds that incorporate an acetal protecting group ortho to the point of fusion, the acid-lability of the Boc function becomes a synthetic advantage rather than a liability. The Fmoc congener (2‑Fmoc‑amino‑thiazole‑4‑carboxylic acid ethyl ester) requires secondary amine base (piperidine, 20% in DMF) for removal, a condition that induces 18% ring-opening of the 1,3-dioxolane ring within 15 min at 22 °C. In contrast, the current Boc-protected reagent, when exposed to 1.0 M HCl/EtOAc (0 °C, 3 h), liberates the free 2‑amino‑thiazole quantitatively while the acetal remains intact (> 97% retention by 1H‑NMR). This orthogonal stability has enabled a telescoped, three-step sequence—Boc deprotection, imine formation with pyridine‑3‑carboxaldehyde, and oxidative aromatization with DDQ (2.0 equiv, toluene, 80 °C)—that furnishes the fused heterocycle in 54% overall isolated yield over three steps without intermediate purification, compared to 29% for the analogous route starting from the Fmoc analog, where extensive chromatographic recovery was necessitated by acetal degradation.

    Table 2. Performance in a Standardized Amidation Screen (Benzylamine, THF, RT, 16 h)
    SubstrateYield (%)Des-Boc impurity (%)Purity after single trituration (%)
    Ethyl 2-(Boc-amino)thiazole-4-carboxylate931.198.8
    Methyl 2-(Boc-amino)thiazole-4-carboxylate892.496.2
    2-(Boc-amino)thiazole-4-carboxylic acid95a0.599.4
    2-(Fmoc-amino)thiazole-4-carboxylic acid ethyl ester81b94.5

    a Using EDC·HCl (1.05 equiv) and HOBt (1.0 equiv) in DMF at 0 °C → RT.
    b Fmoc removal observed (≥8%) under the basic conditions of amine coupling; yield reflects isolated carboxamide after flash chromatography.

    Scale‑up batches manufactured under current Good Manufacturing Practice (cGMP) for phase‑I clinical supply employ a final recrystallization from ethyl acetate/cyclohexane (1:3 v/v, 10 vol) that reduces palladium content to <5 ppm when cross‑coupling steps are part of the upstream process. Stirred‑bed filtration through an activated carbon mat (depth 3 mm, flow rate 50 L·m−2·h−1) prior to crystallization ensures compliance with the elemental impurity limits for Class 1 metals set in ICH Q3D(R2). Differential scanning calorimetry of the recrystallized material shows a single endothermic melting event (onset 104.3 °C, ΔHfus 102 J·g−1) and thermogravimetric analysis records 0.16% weight loss up to 150 °C, confirming the absence of lattice solvent inclusions that would compromise gravimetric dosing accuracy in weigh‑scoop systems on compaction simulators for solid‑dosage drug product development.

    In custom synthesis programs where the thiazole ester is used as a dipolarophile in 1,3‑dipolar cycloadditions with nitrile oxides, the ethyl ester’s electronic character differentiates it from electron‑richer heterocycles. A kinetic study performed on a parallel synthesizer (Argonaut Advantage Series 3400, 48‑position) using benzonitrile N‑oxide generated in situ from the corresponding hydroximoyl chloride and triethylamine in diethyl ether at 5 °C revealed a second‑order rate constant kcycloadd = 5.8 × 10−3 L·mol−1·s−1, approximately 3.5‑fold lower than that of ethyl thiazole‑4‑carboxylate lacking the 2‑Boc‑amino substituent. The attenuation is attributed to the electron‑withdrawing nature of the carbamate group, which reduces the dienophilic character of the C=N double bond. This rate suppression allows selective mono‑cycloaddition in the presence of a competing terminal alkyne, a selectivity feature exploited in the construction of spirocyclic oxazole‑thiazole hybrids.

    No further sections follow.